Free Trial
NYSEAMERICAN:ASXC

Asensus Surgical (ASXC) Stock Price, News & Analysis

Asensus Surgical logo
$0.35 0.00 (0.00%)
(As of 08/22/2024)

About Asensus Surgical Stock (NYSEAMERICAN:ASXC)

Key Stats

Today's Range
$0.35
$0.35
50-Day Range
N/A
52-Week Range
$0.17
$0.40
Volume
N/A
Average Volume
2.03 million shs
Market Capitalization
$94.74 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$0.35
Consensus Rating
Hold

Company Overview

Asensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, the Middle East, Africa, and Asia. It digitizes the interface between the surgeon and the patient to perform performance-guided surgery for surgeons to deliver outcomes to patients. The company's products include Senhance System, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera for laparoscopic procedures; instruments and other products, including 3mm diameter instruments, 3mm and 5mm hooks, and articulating instruments; and Senhance ultrasonic system, an advanced energy device to deliver controlled energy to ligate and divide tissue. The company was formerly known as TransEnterix, Inc. and changed its name to Asensus Surgical, Inc. in February 2021. Asensus Surgical, Inc. is headquartered in Durham, North Carolina.

Receive ASXC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Asensus Surgical and its competitors with MarketBeat's FREE daily newsletter.

ASXC Stock News Headlines

Buy this coin BEFORE Inauguration Day …
Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $125,000 by the end of his first month in office.
See More Headlines

ASXC Stock Analysis - Frequently Asked Questions

Asensus Surgical's stock was trading at $0.2466 on January 1st, 2024. Since then, ASXC shares have increased by 41.1% and is now trading at $0.3479.
View the best growth stocks for 2024 here
.

Asensus Surgical, Inc. (NYSEAMERICAN:ASXC) announced its quarterly earnings data on Wednesday, November, 3rd. The company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.06) by $0.01. The business had revenue of $2.57 million for the quarter, compared to analyst estimates of $1.02 million. Asensus Surgical had a negative trailing twelve-month return on equity of 184.10% and a negative net margin of 902.25%.

Shares of ASXC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Asensus Surgical investors own include Block (SQ), Digital Turbine (APPS), CrowdStrike (CRWD), ChargePoint (CHPT), SoFi Technologies (SOFI) and Tesla (TSLA).

Company Calendar

Last Earnings
11/03/2021
Today
12/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Current Symbol
NYSEAMERICAN:ASXC
CIK
N/A
Employees
170
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$0.35
High Stock Price Target
$0.35
Low Stock Price Target
$0.35
Potential Upside/Downside
+0.6%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$-78,430,000.00
Net Margins
-902.25%
Pretax Margin
-899.16%

Debt

Sales & Book Value

Annual Sales
$8.58 million
Book Value
$0.13 per share

Miscellaneous

Free Float
264,516,000
Market Cap
$94.74 million
Optionable
Not Optionable
Beta
1.37
(Almost)  Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

This page (NYSEAMERICAN:ASXC) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners